EU grants | Horizon 2020 | SME Instrument

GAEU Consulting helped us to structure our projects based on the criterias applied in the SME instrument. During a full-day workshop we discussed the application strategy and how the clinical content was to be presented. Then GAEU wrote the application and guided us through the process. The Horizon 2020 experts in GAEU proved to be very efficient and professional in their work and had great commitment and interest in our project which resulted in a grant of EUR 4.25 million for clinical validation of a biomarker for early diagnosis of pancreatic cancer. We are very pleased with GAEU Consulting's performance and we highly recommend the company for similar efforts. GAEU Consulting is an excellent advisor suited for excellent innovation projects in the Horizon 2020! 

Last year we asked GAEU Consulting to find a funding scheme that could help us to be ready with a new innovation, a contribution large enough to make a difference to our business. GAEU recommended phase 2 of the SME instrument and has since written the application and guided us through the process; workshops, assistance with application strategies and guidance on what information should be supplemented. We applied for the first time last spring. The application passed the threshold but received no grants due to competition from other companies. GAEU analyzed the situation, gave us valuable feedback from the result and recommended us to reapply, which not only led to improvement of the project but also resulted in a grant of EUR 2.3 million for development of a new solution for analysis in the food industry. We strongly recommend GAEU! We will use them in the future.

We are very pleased with GAEU Consulting's work! Together with GAEUs advisors, we have managed to win in fierce competition with other European companies. This is the result of a focused interaction between Cinnober and GAEU which resulted in a SME Instrument phase 2 grant of EUR 2.5 million for a pioneering project in client clearing for international banks.

The money will be used to analyze the market and develop a solid business plan. Result: a grant of EUR 50 000 for a Horizon SME Intrument phase 1 pre-study, now working with GAEU with a phase 2 application.

We are very pleased to be granted Horizon 2020 funding. This significant amount of money, EUR 2.1, will be spent on the validation of imILTCLS. The studies will be performed in collaboration with hospitals we have an established relationship with: in Marseille, France, Porto, Portugal and in Nottingham, the UK. The grant gives us stronger resources to bring imILTCLS to the market and to offer our method as an option in cancer treatment.